

(21) Application No: 2412566.8
 (22) Date of Filing: 16.02.2023
 Date Lodged: 28.08.2024
 (30) Priority Data:
 (31) 63310751 (32) 16.02.2022 (33) US
 (86) International Application Data:
 PCT/US2023/062731 En 16.02.2023
 (87) International Publication Data:
 WO2023/159120 En 24.08.2023

(51) INT CL:
 A61K 31/553 (2006.01) A61K 9/20 (2006.01)
 A61K 31/395 (2006.01) A61K 31/55 (2006.01)
 A61K 31/33 (2006.01) A61P 29/00 (2006.01)
 (56) Documents Cited:
 US 20210238152 A1 US 20210186931 A1
 US 20200390781 A1 US 20200179398 A1
 Biochemical Pharmacology, 2021, Korkmaz et al, "Cathepsin C inhibition as a potential treatment strategy in cancer".
 (58) Field of Search:
 INT CL A61K, A61P
 Other: Clarivate analytics, Pubchem, Google Scholar, Google Patents.

(71) Applicant(s):
 INSMED INCORPORATED
 700 US Highway 202/206, Bridgewater,
 NJ 08807-17004, United States of America
 (72) Inventor(s):
 Ariel Teper
 Andrea Maes
 Marcela Vergara
 Christina Ramirez
 (74) Agent and/or Address for Service:
 Cooley (UK) LLP
 22 Bishopsgate, London, EC2N 4BQ, United Kingdom

(54) Title of the Invention: **Certain N-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa**
 Abstract Title: **Certain N-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa**

(57) The present disclosure relates to methods for treating hidradenitis suppurativa with a composition comprising an effective amount of a N-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamide DPP1 inhibitor compound of Formula (I) or a pharmaceutically acceptable salt thereof. In one embodiment, the compound of Formula (I) is (2S)-N-((1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide (brensocaticib).





Figure 1